Silo Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on August 14, 2026, regarding Silo Pharma, Inc. (Nasdaq: SILO). The filing details the outcomes of the Company's Annual Meeting of Shareholders and a subsequent amendment to its Articles of Incorporation.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Corporate Actions
- Authorized Share Increase: Shareholders approved an amendment to increase the number of authorized Common Stock shares from 6,666,667 to 250,000,000. The Certificate of Amendment was filed on August 14, 2026.
- Board of Directors: All four nominees (Eric Weisblum, Wayne Linsley, Kevin Munoz, and Jeff Pavell) were re-elected to the Board of Directors.
- Auditor Ratification: Shareholders ratified the appointment of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Meeting Adjournment: Shareholders approved a proposal authorizing the adjournment of the Annual Meeting if necessary to solicit additional proxies.
Voting Results
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| Election of Directors (All 4) | ~359,300 each | ~7,400 each | N/A | 330,532 |
| Ratification of Auditor | 690,743 | 2,571 | 3,994 | N/A |
| Common Stock Increase | 498,224 | 190,599 | 8,485 | 0 |
| Adjournment Proposal | 556,797 | 131,873 | 8,638 | 0 |
Note: The filing text contains a clerical reference to a "Reverse Stock Split Proposal" within the description of Proposal 3, but the context and vote results clearly pertain to the "Common Stock Increase Proposal."
Guidance, Outlook, and Risks
The filing does not contain management commentary on future financial guidance, operational outlook, specific risks, or contingencies. The primary focus is the administrative completion of the shareholder vote and the capital structure amendment.
Key Facts for Investor Verification
- Verify the impact of increasing authorized shares from ~6.7 million to 250 million on potential future dilution.
- Confirm the filing of the Certificate of Amendment (Exhibit 3.1) with the State of Nevada.
- Review the Definitive Proxy Statement filed on June 30, 2026, for detailed rationale behind the share increase.
- Note the significant number of broker non-votes (330,532) on the director elections, indicating shares held in street name where brokers lacked discretionary voting power.